Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

Highlights

The phase 1-2 clinical trial of CTNS-RD-04 demonstrates that autologous hematopoietic stem-cell (HSC) gene therapy is a feasible and potentially transformative approach for treating cystinosis. Key highlights include:

• Sustained and highly polyclonal hematopoietic reconstitution was achieved in all six participants, with vector copy numbers (VCN) remaining stable for up to 63 months.
• The therapy led to a significant reduction in white-cell cystine levels, a primary marker of disease burden, allowing for the withdrawal of oral cysteamine.
• The safety profile was primarily characterized by adverse events related to myeloablative conditioning rather than the gene therapy product itself, with no evidence of insertional mutagenesis or monoclonal expansion.

Background: The Unmet Need in Cystinosis

Cystinosis is a rare, multisystemic lysosomal storage disorder caused by loss-of-function mutations in the CTNS gene. This gene encodes cystinosin, a critical transmembrane protein responsible for transporting the amino acid cystine out of lysosomes. When cystinosin is absent or dysfunctional, cystine accumulates and crystallizes within lysosomes across all tissues, leading to progressive organ damage. The kidneys are particularly vulnerable, with patients typically developing Fanconi syndrome in infancy and progressing to end-stage renal disease (ESRD) by the second decade of life without intervention.

The current standard of care involves the cystine-depleting agent cysteamine. While cysteamine has significantly improved life expectancy, it is far from a cure. The treatment requires a rigorous every-six-hour dosing schedule, carries significant gastrointestinal side effects, and produces a sulfurous odor that often leads to poor compliance. More importantly, cysteamine delays but does not prevent the long-term systemic complications of the disease, such as hypothyroidism, diabetes, myopathy, and ophthalmic issues. There is a profound clinical need for a therapy that addresses the underlying genetic defect and provides continuous, systemic cystinosin expression.

Study Design and Methodological Rigor

This phase 1-2, open-label, single-arm clinical study (NCT03897361) evaluated the safety and preliminary efficacy of CTNS-RD-04. The investigational product consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a lentiviral vector (pCCL-human-CTNS) carrying the human CTNS complementary DNA under the control of the constitutive elongation factor 1 alpha (EF1α) promoter.

The study enrolled six adult participants (aged 20 to 46 years). The protocol involved mobilizing and harvesting the patients’ own CD34+ cells, followed by myeloablative conditioning with busulfan to create space in the bone marrow for the genetically modified cells. Following the infusion of CTNS-RD-04, patients were monitored for engraftment, safety, and biological markers of cystinosis. A critical aspect of the study design was the planned withdrawal of systemic cysteamine therapy before infusion and the withdrawal of cysteamine eyedrops one month post-myeloablation, allowing for a clear assessment of the gene therapy’s independent effect on cystine levels.

Key Findings: Safety and Hematopoietic Reconstitution

The primary end points focused on safety and the side-effect profile. Across a follow-up period ranging from 29 to 63 months, the investigators reported a total of 217 adverse events. The majority of these events were mild (Grade 1) or moderate (Grade 2) and were categorized as expected consequences of the busulfan conditioning regimen (e.g., alopecia, nausea, mucositis, and cytopenias) or manifestations of the underlying cystinosis. Importantly, there were no serious adverse events directly attributed to the CTNS-RD-04 drug product.

From a hematological perspective, all six patients achieved successful and sustained engraftment. Neutrophil and platelet recovery occurred within expected timeframes for autologous HSC transplantation. Integration site analysis (ISA) was performed to monitor for potential genotoxicity. The results showed a highly polyclonal pattern of reconstitution in all patients, with no evidence of dominant clones or insertional mutagenesis near known oncogenes. This provides reassuring evidence regarding the safety of the lentiviral vector platform used in this study.

The vector copy numbers (VCN) in peripheral blood mononuclear cells were a key measure of the efficiency of the gene transfer. At 24 months post-infusion, VCNs ranged from 0.51 to 2.67 copies per diploid genome. These levels remained stable throughout the long-term follow-up, suggesting that the modified stem cells successfully established a permanent reservoir of cystinosin-producing cells in the bone marrow.

Clinical Efficacy: Systemic Cystine Depletion

The secondary end points focused on efficacy, primarily measured by white-cell cystine levels. In the five patients who achieved higher VCNs, there was a consistent and significant decrease in intracellular cystine levels compared to their baseline levels while on cysteamine therapy. This reduction is particularly notable because it occurred in the absence of exogenous cysteamine.

Patient 4 served as a critical data point for understanding the dose-response relationship. This participant received a product with the lowest VCN (0.59) and subsequently showed the least reduction in white-cell cystine levels. This suggests that a minimum threshold of transgene expression is required to achieve therapeutic cystine depletion. In the other five participants, the cystine levels were maintained at or below the therapeutic targets traditionally set for cysteamine treatment, indicating that the gene therapy provided a continuous and effective metabolic correction.

Beyond blood markers, the study looked for evidence of tissue-level improvement. Although the primary focus was on safety and white-cell markers, the stabilization of organ function in these adult patients—who already had significant disease-related damage—is an encouraging sign. Further longitudinal data will be required to determine if this therapy can prevent the progression of renal failure or other late-stage complications in younger pediatric populations.

Expert Commentary: Mechanistic Insights and Limitations

The biological mechanism behind the success of HSC gene therapy in a non-hematological disease like cystinosis is fascinating. Preclinical studies by Dr. Stephanie Cherqui’s team, which laid the foundation for this trial, suggested that the mechanism of action involves “cross-correction.” The progeny of the transplanted HSCs (macrophages and other leukocytes) infiltrate various tissues and transfer functional cystinosin or the CTNS mRNA to the diseased host cells. This transfer is thought to occur via tunneling nanotubes (TNTs) or microvesicles, effectively “rescuing” cells that lack the protein.

However, clinicians must view these results with cautious optimism. This was a small, phase 1-2 study involving only six adult participants. While the safety and biological signal are strong, several questions remain. First, the use of busulfan conditioning carries significant risks, including infertility and a potential, albeit small, risk of secondary malignancies. For pediatric patients, the benefit-risk ratio of myeloablation must be carefully weighed. Second, while white-cell cystine levels are a standard biomarker, the ultimate goal is the preservation of organ function (e.g., GFR stabilization, prevention of retinopathy). Longer-term data and studies in younger cohorts will be essential to prove that CTNS-RD-04 can alter the natural history of the disease.

Furthermore, the experience of Patient 4 highlights the technical challenges of ex vivo gene therapy. Ensuring high-quality cell products with optimal VCN is vital for clinical success. Future iterations of the protocol may focus on optimizing the transduction process or the conditioning regimen to ensure all patients reach the therapeutic threshold.

Conclusion and Future Directions

The results of this study represent a landmark achievement in the treatment of cystinosis. CTNS-RD-04 has demonstrated that a single infusion of gene-modified stem cells can provide a durable, systemic source of cystinosin, reducing the toxic accumulation of cystine without the need for daily oral medication. For patients who have spent their lives tethered to a grueling medication schedule, the prospect of a “one-and-done” therapy is revolutionary.

As the trial continues and moves toward larger, multi-center phases, the focus will shift toward assessing long-term organ preservation and refining the patient selection criteria. If these results are sustained, HSC gene therapy could become the first-line treatment for cystinosis, potentially preventing the devastating systemic complications that currently define the lives of those born with this condition.

Funding and ClinicalTrials.gov

This study was funded by the California Institute for Regenerative Medicine (CIRM), the Cystinosis Research Foundation, and the National Institutes of Health. ClinicalTrials.gov number: NCT03897361.

References

1. Barshop BA, Ball ED, Benador N, et al. Hematopoietic Stem-Cell Gene Therapy for Cystinosis. N Engl J Med. 2026;394(8):753-762. doi:10.1056/NEJMoa2506431.
2. Cherqui S, Courtoy PJ. The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives. Nat Rev Nephrol. 2017;13(2):115-131.
3. Nesterova G, Gahl WA. Cystinosis: the evolution of a soluble enzyme deficiency into a systemic storage disease. Pediatr Nephrol. 2013;28(1):51-59.
4. Harrison F, Yeagy BA, Rocca CJ, et al. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther. 2013;21(2):433-444.